|
1
|
Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.
|
Immunology
|
2009
|
1.75
|
|
2
|
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
|
Mol Genet Metab
|
2007
|
1.61
|
|
3
|
AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
|
J Gene Med
|
2006
|
1.17
|
|
4
|
Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
|
J Inherit Metab Dis
|
2010
|
1.10
|
|
5
|
STR/ort mice, a model for spontaneous osteoarthritis, exhibit elevated levels of both local and systemic inflammatory markers.
|
Comp Med
|
2011
|
0.95
|
|
6
|
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling.
|
Int J Oncol
|
2011
|
0.94
|
|
7
|
Identification of the chondrocyte lineage using microfibril-associated glycoprotein-2, a novel marker that distinguishes chondrocytes from synovial cells.
|
Tissue Eng Part C Methods
|
2010
|
0.76
|